Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Addressing disparities in chemotherapy acceptance: barriers and potential solutions

Inimfon Jackson • 30 May 2025
ASCO 2025
General

Inimfon Jackson, MD, PhD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses disparities in chemotherapy acceptance and potential strategies to address them. She emphasizes that the most significant disparities exist in patients on public insurance or with no insurance, as well as non-Hispanic Black patients. Dr Jackson highlights the importance of a multi-pronged approach to address distrust of providers, identify patients at risk, and facilitate informed decision-making. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Inimfon Jackson

Addressing access barriers and guideline-concordant breast cancer care
1:07
Addressing access barriers and guideline-concordant breast cancer care
Inimfon Jackson • 10 Dec 2025
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
2:28
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
Inimfon Jackson • 10 Dec 2025
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
1:53
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
Inimfon Jackson • 30 May 2025
Navigating discussions with patients who have high-risk genomics but are reluctant about chemo
0:57
Navigating discussions with patients who have high-risk genomics but are reluctant about chemo
Inimfon Jackson • 30 May 2025

Related Videos

Educational impact of a guideline-based hematology-oncology bootcamp curriculum
2:41
Educational impact of a guideline-based hematology-oncology bootcamp curriculum
Chinmay Jani • 31 May 2026
Reduced-dose radiation achieves local control in ATM-mutated cancers: Phase II results
1:26
Reduced-dose radiation achieves local control in ATM-mutated cancers: Phase II results
Amy Xu • 31 May 2026
Standardizing re-irradiation data and integrating patient biology
0:52
Standardizing re-irradiation data and integrating patient biology
Laure Marignol • 16 May 2026
Biology-driven approaches to safer re-irradiation strategies
0:59
Biology-driven approaches to safer re-irradiation strategies
Laure Marignol • 16 May 2026
The content of VJOncology is intended for healthcare professionals